1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Changzhou Qianhong Bio-Pharma Co., Ltd. Class A

Changzhou Qianhong Bio-Pharma Co., Ltd. Class A

SSZSE:002550
6.27
CNY
+0.09
(+1.46%)
0.19EPS
28.93P/E
7.95BMarket Cap
Oct 30Next Earn
Changzhou Qianhong Bio-Pharma Co., Ltd. Class A
SZSE:002550
(Shenzhen Stock Exchange)

Recent

price

6.27

P/E

ratio

28.93

div

yld

1.93%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.19
0.6
0.57
0.67
0.63
0.6
0.62
0.82
1.02
1.34
1.39
1.55
1.78
1.4
1.2
1.26
1.23
Revenue per Share
0.16
0.12
0.13
0.14
0.19
0.21
0.18
0.14
0.17
0.21
-0.11
0.15
0.25
0.14
0.28
0.32
0.21
Basic EPS, GAAP
0.17
0.1
0.11
0.03
0.13
0.06
0.07
- -
-0.06
0.05
0.21
0.01
-0.11
0.33
0.33
0.18
- -
Free Cash Flow per Basic Share
0.13
0.03
0.04
0.06
0.06
0.08
0.09
0.09
0.1
0.14
0.26
0.13
0.12
0.12
0.12
0.12
0.12
Dividend per Share
0.41
1.34
1.43
1.51
1.64
1.78
1.88
1.9
1.98
1.82
1.63
1.66
1.91
1.92
1.97
2.16
2.14
Book Value per Share
0.4
1.31
1.39
1.44
1.57
1.71
1.8
1.83
1.87
1.72
1.52
1.55
1.8
1.77
1.78
1.95
1.91
Tangible Book Value per Share
963
1,230
1,282
1,290
1,290
1,272
1,247
1,307
1,302
1,250
1,200
1,207
1,294
1,299
1,272
1,246
1,237
Basic Weighted Avg Shares
1,145
738
729
861
815
757
776
1,065
1,322
1,675
1,668
1,875
2,304
1,814
1,526
1,571
1,526
Sales/Revenue/Turnover
15.57
19.62
18.52
17.15
22.82
26.19
20.37
11.89
10.53
14.58
13.6
8.66
10.78
9.15
19.29
21.16
19.23
Operating Margin (%)
11
13
17
22
21
20
28
61
61
65
70
69
65
69
65
66
- -
Depreciation Expense
151
152
162
187
245
267
224
183
221
263
-132
181
323
182
356
399
265
Net Income, GAAP
13.68
14.98
14.9
15.95
15.35
13.43
15.07
18.16
16.86
14.51
- -
11
11.22
12.21
15.83
17.09
16.03
Effective Tax Rate (%)
13.15
20.64
22.21
21.73
30.08
35.29
28.91
17.18
16.75
15.67
-7.92
9.66
14.04
10.02
23.33
25.38
17.4
Profit Margin (%)
357
1,659
1,715
1,431
1,455
1,668
1,302
1,726
1,827
1,547
1,266
1,274
1,409
1,420
1,470
1,684
1,700
Working Capital
29
20
- -
- -
27
- -
- -
- -
50
- -
- -
- -
- -
- -
- -
3
3
LT Debt
414
1,766
1,869
1,971
2,133
2,294
2,425
2,453
2,538
2,333
2,065
2,118
2,433
2,474
2,517
2,766
2,727
Total Equity
33.61
12.35
8.2
9.13
10.93
10.76
8.14
6.16
7.21
9.08
- -
8.64
13.59
7.13
13.21
14.29
8.95
Return on Invested Capital (%)
37.38
13.63
9.09
10.03
12.03
11.75
8.81
7.26
8.52
10.07
- -
8.22
13.99
7.52
15
16.01
10.67
Return on Capital (%)
47.2
14.39
9.12
9.95
12.15
12.22
9.6
7.57
8.91
10.8
-5.98
8.61
14.13
7.41
14.32
15.09
9.8
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
30
LT Borrowings
- -
- -
- -
LT Finance Leases
3
3
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,280
1,280
1,280
Market Capitalization
10,059
9,778
7,948

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,908
2,029
1,999
Cash, Cash Equivalents & STI
1,085
1,282
1,142
Accounts Receivable, Net
257
216
238
Inventories
372
404
405
Total Current Liabilities
224
278
299
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
30
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.15%
6.15%
9.92%
Free Cash Flow
-392.16%
-345.89%
-48.18%
Net Income, GAAP
-23.97%
-18.91%
12.01%
Sales/Revenue/Turnover
9.12%
0.22%
2.95%
Total Cash Common Dividend
8.74%
-10.45%
-0.72%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
461
394
352
319
1,526
2025
451
411
- -
356
1,571
2026
358
400
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.08
0.06
0.1
0.04
0.28
2025
0.13
0.08
- -
0.01
0.32
2026
0.07
0.05
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.12
- -
- -
0.12
2025
- -
0.12
- -
- -
0.12
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Changzhou Qianhong Biopharma Co., Ltd. (002550.SZ) manufactures and markets polysaccharide and protease biopharmaceuticals, focusing on medicinal enzymes and heparin-based products. The company produces active pharmaceutical ingredients and finished dosage forms including pancreatic kininogenase series for microcirculation disorders; asparaginase series for acute lymphoblastic leukemia; compound digestive enzyme capsules (II) and elastase series for digestive support; heparin sodium and calcium; and low molecular weight heparins such as nadroparin calcium, enoxaparin sodium, and dalteparin sodium, offered in tablets, hard capsules, lyophilized powders, injections, pre-filled syringes, and raw materials. It operates primarily in the cardiovascular, circulatory, digestive, and anti-tumor segments, serving domestic hospitals and exporting to Europe, North America, South America, and Southeast Asia. Founded in 1971 and headquartered in Changzhou, Jiangsu Province, China, the company maintains holding subsidiaries including Jiangsu Zhonghong Bioengineering Pharmaceutical Research Institute Co., Ltd., Changzhou Yingnuo Shengkang Biomedical Technology Co., Ltd., Changzhou Qianhong Health Technology Co., Ltd., and Qianhong Biochemical Pharmaceutical (Hubei) Co., Ltd. In recent developments, Changzhou Qianhong signed an agreement in September 2022 for a new API production base in Zhongxiang, Hubei Province to expand manufacturing capacity; plans to raise up to 1 billion yuan as of November 2024 for acquisitions and technological upgrades; and advances a pipeline with candidates like ZHB-111 in Phase 2 for growth hormone deficiency, alongside investments in oncology and autoimmune therapies.